U.S. markets closed

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)

NSE - NSE Real Time Price. Currency in INR
Add to watchlist
528.85-0.10 (-0.02%)
At close: 3:29PM IST
Full screen
Loading interactive chart...
  • Sun Pharma latest to sell COVID-19 drug favipiravir in India
    Reuters

    Sun Pharma latest to sell COVID-19 drug favipiravir in India

    India's Sun Pharmaceutical Industries Ltd said on Tuesday it would soon begin selling its version of favipiravir, becoming the latest generic drugmaker to supply the antiviral to treat COVID-19 in the world's third worst-hit nation. Favipiravir, along with another antiviral, remdesivir, has emerged as one of the most sought-after drugs at hospitals fighting COVID-19 in India, which saw a surge of 50,000-plus infections for the sixth straight day on Tuesday. Sun's version of favipiravir, to be called FluGuard, will cost 35 rupees (47 cents) per 200 mg tablet, making it the cheapest version available.

  • Sun Pharma testing plant-based drug as potential COVID-19 treatment
    Reuters

    Sun Pharma testing plant-based drug as potential COVID-19 treatment

    Indian drugmaker Sun Pharmaceutical Industries Ltd said on Friday it was testing a plant-derived drug, AQCH, for the potential treatment of COVID-19 as part of a mid-stage trial, with results expected by October. AQCH is derived from tropical, climbing shrub cocculus hirsutus, which is used in Asia for its apparent medicinal properties. The company said the trial will be conducted across 12 centers in India in 210 patients and a human safety study of the drug has been completed.

  • Sun Pharma to test pancreatitis drug in COVID-19 patients in India
    Reuters

    Sun Pharma to test pancreatitis drug in COVID-19 patients in India

    Drugmaker Sun Pharmaceutical Industries Ltd said on Friday it has received Indian regulatory approval to start clinical trials of a pancreatitis drug in COVID-19 patients. The company joins other Indian drugmakers Glenmark Pharmaceuticals Ltd and Strides Pharma Science Ltd that are conducting trials in India for potential drugs for COVID-19, which currently has no approved treatment or vaccine. Sun Pharma said http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200529:nBSE5stp4F the pancreatitis drug, nafamostat mesilate, has been "identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany".